Results There were 1,120 case subjects and 41,409 control subjects in the final analysis. There was a significant reduction of CVD development for consuming ephedrarelated CHP (OR=0.183, p<0.001). Only three items (Xiao Xu Ming Shang OR=2.212, p<0.001; Gui Qi Shao Yao Zhi Mu Shang OR=1.701, p<0.001; She Gan Ma Huang Shang OR=1.441, p=0.006) out of a total of 24 ephedra-related CHP were associated with the risk of CVD development. No statistically linear dose-response relationship was observed with the prescribed dose of ephedra.
free text keywords: Complementary and alternative medicine, General Medicine, Poster Presentation, Medicine, business.industry, business, Traditional medicine, Population based, Disease risk, Xiao-xu-ming, Control subjects, Case-control study